THINKMD Secures More Than $ 6 Million To Accelerate Growth – Leading Global Healthcare Organizations Support Expansion Of Advanced Clinical Solutions In Low And Middle Income Countries
âNow more than ever, we need to equip frontline healthcare workers with the tools to deliver clinical quality to those most often left behind in the healthcare response,â said Chris Powell, CEO of THINKÂ®.
BURLINGTON, Vermont (PRWEB)
December 15, 2021
THINKMD, a Vermont-based healthcare technology company, received a $ 2.3 million technology development grant from the Bill & Melinda Gates Foundation and closed a $ 4 million investor-led funding round in health technologies.
THINKMD is a mission-driven, social impact technology company that aims to make its clinical intelligence technology universally available so that anyone, anywhere can make better healthcare decisions for them. himself and his community. The company’s solutions are currently active in 10 countries and help any user identify how sick a person is, what illness they may have and what are the next steps to take. Validation studies have shown that clinical evaluations and triage recommendations of THINKÂ® correlate up to 95% with those of healthcare professionals.
The Bill & Melinda Gates Foundation grant will support the next phase of THINKMD’s technological expansion, including the development of a clinical application programming interface (API) based on Fast Healthcare Interoperability. Resources (FHIR) which will help advance its technology globally. The grant will also accelerate the company’s machine learning and data analysis efforts, as well as field implementations of THINKÂ® solutions to demonstrate scalability and impact.
âSupport from the Bill & Melinda Gates Foundation enables exploration of the myriad of ways the THINKMD Clinical Intelligence API can be distributed globally,â said Dr. Barry Finette, co-founder of THINKMD . “These funds will allow us to adapt our proven model to a variety of contexts and settings, and to continue to expand and increase the health impact we strive to achieve.”
The company, which recently appointed veteran digital health executive Chris Powell as CEO, also finalized a $ 4 million funding round in October. This capital injection will allow the company to enter its next phase of growth. Investors in the cycle include Save the Children Federation, Save the Children Impact Fund Ltd. and the Sorenson Impact Foundation.
âNow more than ever, we need to equip frontline healthcare workers with the tools to deliver clinical quality to those most often left behind in the healthcare response,â said Chris Powell, CEO of THINKÂ®. âWe feel privileged that global healthcare leaders recognize that THINKÂ®’s solution can help close part of the gap. “
Save the Children President and CEO Janti Soeripto said: âThe power of innovation to improve children’s health outcomes cannot be overstated. In the countries where we work, the quality of healthcare is often limited due to the shortage of healthcare providers or the limitations of healthcare delivery. We’re excited to partner with THINKÂ® to help achieve a future where no child under the age of five dies from preventable causes.
THINKMD’s mission is to make clinical intelligence technology universally accessible so that anyone, anywhere, can make better healthcare decisions for themselves and their community. A social impact company based in Burlington, Vt., THINKÂ® clinical intelligence technology helps any user identify how sick a person is, what illness they may have, and what are the appropriate next steps to take. The scientifically validated technology, which also addresses the COVID-19 pandemic, uses guidelines compliant with the World Health Organization (WHO). THINKMD empowers users, healthcare delivery organizations and governments with acquired data that informs accurate clinical and public health decision making. THINKMD is currently active in 10 countries (Bangladesh, Indonesia, Zambia, Kenya, Togo, Sudan, Somalia, Nigeria, South Africa and USA). Learn more at http://www.thinkmd.org.
Share the article on social media or by email: